3642-95-3

Usage

Uses

Used in Pharmaceutical Industry:
(5alpha,17alpha)-pregn-2-en-20-yn-17-ol is used as an active ingredient in oral contraceptive pills for the purpose of preventing pregnancy. It achieves this by inhibiting ovulation, altering the cervical mucus to prevent sperm penetration, and thinning the uterine lining to avoid implantation of a fertilized egg.
Additionally, this synthetic hormone is used as a therapeutic agent for treating menstrual disorders, endometriosis, and other conditions related to hormonal imbalances. Its application in these areas is due to its ability to regulate and balance hormone levels in the body, providing relief from symptoms associated with these conditions.
However, it is important to note that the use of (5alpha,17alpha)-pregn-2-en-20-yn-17-ol is associated with potential side effects and risks, such as an increased risk of blood clots, stroke, and heart attack. Therefore, individuals using this chemical should consult with a healthcare provider and undergo regular check-ups to ensure its safe and effective use.

Upstream product

• 14639-79-3 5α-androst-2-en-17-one 
• 74-86-2 acetylene 
• 29041-91-6 2α-bromo-17β-hydroxy-5α-androstan-3-one 
• 2639-53-4 (5α,17β)-androst-2-en-17-ol 
• 10429-07-9 3β-tosyloxy-5α-androstan-17-one 
• 4301-14-8 acetylenemagnesium bromide 
• 481-29-8 Epiandrosterone 

Relevant academic research and scientific papers

In vitro metabolism studies of desoxy-methyltestosterone (DMT) and its five analogues, and in vivo metabolism of desoxy-vinyltestosterone (DVT) in horses

The positive findings of norbolethone in 2002 and tetrahydrogestrinone in 2003 in human athlete samples confirmed that designer steroids were indeed being abused in human sports. In 2005, an addition to the family of designer steroids called 'Madol' [also known as desoxy-methyltestosterone (DMT)] was seized by government officials at the US-Canadian border. Two years later, a positive finding of DMT was reported in a mixed martial arts athlete's sample. It is not uncommon that doping agents used in human sports would likewise be abused in equine sports. Designer steroids would, therefore, pose a similar threat to the horseracing and equestrian communities. This paper describes the in vitro metabolism studies of DMT and five of its structural analogues with different substituents at the 17α position (R￡H, ethyl, vinyl, ethynyl and 2H3-methyl). In addition, the in vivo metabolism of desoxy-vinyltestosterone (DVT) in horses will be presented. The in vitro studies revealed that the metabolic pathways of DMT and its analogues occurred predominantly in the A-ring by way of a combination of enone formation, hydroxylation and reduction. Additional biotransformation involving hydroxylation of the 17α-alkyl group was also observed for DMT and some of its analogues. The oral administration experiment revealed that DVT was extensively metabolised and the parent drug was not detected in urine. Two in vivo metabolites, derived respectively from (1) hydroxylation of the A-ring and (2) di-hydroxylation together with A-ring double-bond reduction, could be detected in urine up to a maximum of 46 h after administration. Another in vivo metabolite, derived from hydroxylation of the A-ring with additional double-bond reduction and di-hydroxylation of the 17α-vinyl group, could be detected in urine up to a maximum of 70 h post-administration. All in vivo metabolites were excreted mainly as glucuronides and were also detected in the in vitro studies.